Kristi Rosa

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Experts from Emory University School of Medicine, Massachusetts General Hospital, and Hospital of the University of Pennsylvania, highlight the exciting research being conducted at their respective institutions.

Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.

Benjamin Weinberg, MD, provides insight into NRG1 fusions, the effectiveness of afatinib in patients harboring these fusions, and future research being done in NRG1 fusion–positive gastrointestinal cancers.

David Samuel Dicapua Siegel, MD, highlights key research in multiple myeloma and the renewed focus on improving quality of life.

Jane Meisel, MD, provides insight on how genomic assays are helping to individualize treatment plans and strategies to determine the optimal duration of endocrine therapy.

Matthew Steliga, MD, discusses key surgical updates in lung cancer and the shifting role of surgery with the emergence of novel therapies.

Celestia S. Higano, MD, FACP, shares insight on key trials in prostate cancer.

Mollie Meek, MD, highlights key lung cancer screening trials, offered insight into how to successfully implement an effective program, and stressed that collaboration is critical in order to provide the best patient care.

David F. McDermott, MD, provides insight on pembrolizumab in non-clear cell renal cell carcinoma (RCC) and the next steps for research in the overall RCC paradigm.

Claud M. Grigg Jr, MD, highlights data from pivotal trials with combinations in both clear cell and non-clear cell renal cell carcinoma, as well as challenges with identifying biomarkers for immunotherapy.

Monocytic myeloid-derived suppressor cells increased with ibrutinib treatment in a preclinical model of chronic lymphocytic leukemia, suggesting a role for ITK inhibition in this cell population.

Brian Van Tine, MD, highlights the latest developments in soft tissue sarcoma, including data from key trials and further research being conducted in the rare tumor field.

Lecia V. Sequist, MD, MPH, highlights recent developments in NSCLC treatment and shared key questions that still need to be addressed.

Jing-Zhou Hou, MD, PhD, highlights the research being conducted in the realm of lymphoma, including positive and negative trials that have read out in the space, and provides insight into novel approaches under investigation.

James M. Rossetti, DO, discusses strategies for symptom management, tools available for risk stratification, and updated data with some of the pivotal agents in myeloproliferative neoplasms.

Annie Im, MD, discusses the importance of minimal residual disease in acute lymphoblastic leukemia, the role of transplant, and novel treatment approaches under investigation.

Anastasios Raptis, MD, highlights promising combinations under investigation in the frontline setting and remaining challenges in multiple myeloma.

Kleber Yotsumoto Fertrin, MD, PhD, provided insight into the new options that have emerged in the treatment landscape of benign hematologic malignancies.

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

Thomas E. Stinchcombe, MD, discusses the numerous ALK inhibitors available in the treatment of ALK-positive non–small cell lung cancer, ongoing efforts to combat resistance, and sequencing challenges that have emerged.

Daniel Gomez, MD, provides insight on the different treatment approaches under exploration for patients with oligometastatic disease.

The FDA has granted an approval to a prefilled syringe for lanreotide (Somatuline Depot), which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.

Nirav S. Dhruva, MD, highlightes key advances made in non–small cell lung cancer, the importance of PD-L1 expression testing, and ongoing efforts to bridge the gap between community and academic centers in lung cancer care.

Chad Pecot, MD, discusses practice-changing immunotherapy research that has read out in squamous non–small cell lung cancer, emerging biomarkers under investigation, and logical combinations that beg for further exploration.

Neal E. Ready, MD, PhD, highlights recent advances that have been made in the treatment of small cell lung cancer, the promise of immunotherapy, and opportunities to improve patient care.